Biomea Fusion, Inc. updated the anticipated timing for topline results from its ongoing Phase I GLP-131 trial for BMF-650 in obese, otherwise healthy volunteers, which are now expected in October 2026. Biomea Fusion, Inc. operates as a clinical-stage biopharmaceutical company focused on developing novel therapeutics.
